GR3030369T3 - Transdermal drug delivery system - Google Patents
Transdermal drug delivery systemInfo
- Publication number
- GR3030369T3 GR3030369T3 GR990401461T GR990401461T GR3030369T3 GR 3030369 T3 GR3030369 T3 GR 3030369T3 GR 990401461 T GR990401461 T GR 990401461T GR 990401461 T GR990401461 T GR 990401461T GR 3030369 T3 GR3030369 T3 GR 3030369T3
- Authority
- GR
- Greece
- Prior art keywords
- therapeutic agent
- pct
- cyclodextrin
- date jan
- sec
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9413866A GB2290964A (en) | 1994-07-08 | 1994-07-08 | Transdermal drug delivery system |
PCT/FI1995/000358 WO1996001626A1 (en) | 1994-07-08 | 1995-06-20 | Transdermal drug delivery system |
Publications (1)
Publication Number | Publication Date |
---|---|
GR3030369T3 true GR3030369T3 (en) | 1999-09-30 |
Family
ID=10758074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR990401461T GR3030369T3 (en) | 1994-07-08 | 1999-05-28 | Transdermal drug delivery system |
Country Status (12)
Country | Link |
---|---|
US (1) | US5817332A (el) |
EP (1) | EP0764020B1 (el) |
JP (1) | JP3734267B2 (el) |
AT (1) | ATE178485T1 (el) |
AU (1) | AU2740595A (el) |
CA (1) | CA2193129C (el) |
DE (1) | DE69508938T2 (el) |
DK (1) | DK0764020T3 (el) |
ES (1) | ES2130622T3 (el) |
GB (1) | GB2290964A (el) |
GR (1) | GR3030369T3 (el) |
WO (1) | WO1996001626A1 (el) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0838225A3 (en) * | 1996-10-25 | 1999-03-24 | Hiji, Yasutake | Aqueous local anesthetic solution |
US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
DE19810951B4 (de) * | 1998-03-13 | 2005-09-29 | Ciba Speciality Chemicals Holding Inc. | Verwendung eines textilen Materials als transdermales Abgabesystem sowie Verfahren zu seiner Herstellung |
DE19814087A1 (de) | 1998-03-30 | 1999-10-14 | Lohmann Therapie Syst Lts | Feuchtigkeitsaktivierbares therapeutisches System |
DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
US6719997B2 (en) | 2000-06-30 | 2004-04-13 | Dermatrends, Inc. | Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers |
US20030104041A1 (en) * | 1999-12-16 | 2003-06-05 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
WO2001043775A2 (en) * | 1999-12-16 | 2001-06-21 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
US6586000B2 (en) | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
US6673363B2 (en) | 1999-12-16 | 2004-01-06 | Dermatrends, Inc. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
US6582724B2 (en) | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
US6689378B1 (en) | 1999-12-28 | 2004-02-10 | Kimberly-Clark Worldwide, Inc. | Cyclodextrins covalently bound to polysaccharides |
US7179483B2 (en) | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US20050227911A1 (en) * | 2001-09-28 | 2005-10-13 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
US20050233003A1 (en) * | 2001-09-28 | 2005-10-20 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid |
US6878693B2 (en) | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
US7700851B2 (en) * | 2001-11-13 | 2010-04-20 | U.S. Smokeless Tobacco Company | Tobacco nicotine demethylase genomic clone and uses thereof |
PL373780A1 (en) * | 2002-02-25 | 2005-09-19 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
US7759506B2 (en) | 2002-02-25 | 2010-07-20 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
PT1629844E (pt) | 2004-07-13 | 2007-10-17 | Bayer Schering Pharma Oy | Sistema de distribuição a longo prazo com distribuição súbita inicial controlada |
UA95903C2 (ru) * | 2005-02-24 | 2011-09-26 | Дифьюжен Фармасьютикалз Ллк | Транс-каротиноиды, их синтез, лекарственная форма и применение |
US8287923B2 (en) * | 2005-06-10 | 2012-10-16 | Medical College Of Georgia Research Institute, Inc. | Compositions and methods for treating immune disorders |
US9446017B2 (en) | 2005-08-11 | 2016-09-20 | Augusta University Research Institute, Inc. | Compositions and methods for treating herpes simplex virus |
BRPI0710674A2 (pt) * | 2006-04-07 | 2011-08-23 | Allergan Inc | composições incluindo fármacos relativamente insolúveis em água/não umectáveis e métodos para usar as mesmas |
US9114133B2 (en) | 2006-08-25 | 2015-08-25 | U.S. Dept. Of Veterans Affairs | Method of improving diastolic dysfunction |
JP2010524855A (ja) | 2007-04-13 | 2010-07-22 | ディフュージョン・ファーマシューティカルズ・エルエルシー | 末梢血管疾患の前処置としての、及びその処置における双極性トランスカロテノイドの使用 |
BRPI0818119A2 (pt) * | 2007-10-31 | 2015-08-04 | Diffusion Pharmaceuticals Llc | Uma nova classe de produtos terapêuticos que melhoram difusão de molécula pequena |
EP2445339B1 (en) * | 2009-06-22 | 2019-08-07 | Diffusion Pharmaceuticals LLC | Diffusion enhancing compound and its use with a thrombolytic |
EP2459184A1 (en) | 2009-07-31 | 2012-06-06 | The Brigham and Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
EP2556082B1 (en) | 2010-04-08 | 2017-02-22 | Emory University | Substituted androst-4-ene diones |
CN105287473A (zh) | 2010-06-02 | 2016-02-03 | 扩散药品有限公司 | 包含双极性反式类胡萝卜素的组合物及其应用 |
WO2012129237A2 (en) | 2011-03-20 | 2012-09-27 | Trustees Of Boston University | Therapeutic agent for emphysema and copd |
EP2704726B1 (en) | 2011-05-04 | 2018-10-31 | Trustees of Boston University | Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria |
US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
EP2543370A1 (en) | 2011-07-06 | 2013-01-09 | Georgia Health Sciences University Research Institute, Inc. | Compositions and Methods for Treating Herpes Simplex Virus |
WO2013071049A1 (en) | 2011-11-10 | 2013-05-16 | Trustees Of Boston College | Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity |
WO2014130922A1 (en) | 2013-02-25 | 2014-08-28 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
CA2924141C (en) | 2013-08-22 | 2022-06-07 | The General Hospital Corporation | 5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase |
EP3038625A4 (en) | 2013-08-29 | 2017-08-23 | Trustees of Boston University | Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections |
CA2924188C (en) * | 2013-10-07 | 2018-12-18 | Teikoku Pharma Usa, Inc. | Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions |
KR101827980B1 (ko) | 2013-10-07 | 2018-02-13 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법 |
CA2924236C (en) | 2013-10-07 | 2020-01-07 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
ES2856189T3 (es) | 2013-10-07 | 2021-09-27 | Teikoku Pharma Usa Inc | Métodos y composiciones para el tratamiento del trastorno de hiperactividad por déficit de atención, ansiedad e insomnio utilizando composiciones transdérmicas de dexmedetomidina |
TW201609200A (zh) | 2013-12-18 | 2016-03-16 | 丸石製藥股份有限公司 | 含水型貼劑 |
JP2017501224A (ja) * | 2013-12-18 | 2017-01-12 | ジー・エヌ・ティー・エル・エル・シー | 緑内障の治療用組成物及び方法 |
EP3303286B1 (en) | 2015-06-01 | 2023-10-04 | Cedars-Sinai Medical Center | Compounds that bind to rela of nf-kb for use in treating cancer |
WO2017017631A2 (en) | 2015-07-28 | 2017-02-02 | Vyome Biosciences Pvt. Ltd. | Antibacterial therapeutics and prophylactics |
US10493049B2 (en) | 2016-02-10 | 2019-12-03 | Niracle LLC | Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations |
KR20230014850A (ko) | 2016-03-24 | 2023-01-30 | 디퓨젼 파마슈티컬즈 엘엘씨 | 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도 |
EP3562486B1 (en) | 2016-12-31 | 2024-03-13 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
EP3813802A4 (en) | 2018-06-27 | 2022-06-08 | Bioxcel Therapeutics, Inc. | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM |
TWI772807B (zh) | 2019-05-27 | 2022-08-01 | 日商救急藥品工業股份有限公司 | 外用製劑 |
MX2022000709A (es) | 2019-07-19 | 2022-05-19 | Bioxcel Therapeutics Inc | Regimenes de tratamiento con dexmedetomidina no sedante. |
EP4308088A1 (en) | 2021-11-08 | 2024-01-24 | Weiyong Li | Transdermal drug delivery system for delivering a drug to a patient |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4756710A (en) * | 1985-04-05 | 1988-07-12 | Merck & Co., Inc. | pH-Mediated drug delivery system |
US4749574A (en) * | 1986-04-14 | 1988-06-07 | Fujisawa Pharmaceutical Co., Ltd. | Sustained-release transdermal delivery preparations |
US4781924A (en) * | 1987-11-09 | 1988-11-01 | Alza Corporation | Transdermal drug delivery device |
SE8904296D0 (sv) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
HU210921B (en) * | 1990-03-28 | 1995-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them |
GB9012663D0 (en) * | 1990-06-07 | 1990-08-01 | Erba Carlo Spa | Galenic formulations containing cyclodextrins |
GB9111732D0 (en) * | 1991-05-31 | 1991-07-24 | Orion Yhtymae Oy | The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs |
CA2120748A1 (en) * | 1991-10-16 | 1993-04-29 | Arto Olavi Urtti | Peroral drug delivery system |
US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
-
1994
- 1994-07-08 GB GB9413866A patent/GB2290964A/en not_active Withdrawn
-
1995
- 1995-06-20 US US08/765,766 patent/US5817332A/en not_active Expired - Lifetime
- 1995-06-20 EP EP95922554A patent/EP0764020B1/en not_active Expired - Lifetime
- 1995-06-20 DK DK95922554T patent/DK0764020T3/da active
- 1995-06-20 AU AU27405/95A patent/AU2740595A/en not_active Abandoned
- 1995-06-20 CA CA002193129A patent/CA2193129C/en not_active Expired - Lifetime
- 1995-06-20 ES ES95922554T patent/ES2130622T3/es not_active Expired - Lifetime
- 1995-06-20 JP JP50413396A patent/JP3734267B2/ja not_active Expired - Lifetime
- 1995-06-20 DE DE69508938T patent/DE69508938T2/de not_active Expired - Lifetime
- 1995-06-20 WO PCT/FI1995/000358 patent/WO1996001626A1/en active IP Right Grant
- 1995-06-20 AT AT95922554T patent/ATE178485T1/de active
-
1999
- 1999-05-28 GR GR990401461T patent/GR3030369T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK0764020T3 (da) | 1999-10-18 |
ES2130622T3 (es) | 1999-07-01 |
WO1996001626A1 (en) | 1996-01-25 |
GB9413866D0 (en) | 1994-08-24 |
ATE178485T1 (de) | 1999-04-15 |
DE69508938D1 (de) | 1999-05-12 |
CA2193129A1 (en) | 1996-01-25 |
JP3734267B2 (ja) | 2006-01-11 |
EP0764020A1 (en) | 1997-03-26 |
CA2193129C (en) | 2007-11-06 |
EP0764020B1 (en) | 1999-04-07 |
AU2740595A (en) | 1996-02-09 |
DE69508938T2 (de) | 1999-09-16 |
GB2290964A (en) | 1996-01-17 |
US5817332A (en) | 1998-10-06 |
JPH10502388A (ja) | 1998-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3030369T3 (en) | Transdermal drug delivery system | |
ATE298259T1 (de) | Vorrichtung zur lokalen verabreichung einer arznei in einer körperhöhle | |
RS52577B (en) | ONE-DAY OXYCODON FORMULATIONS | |
ATE267798T1 (de) | Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung | |
ATE237330T1 (de) | Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung | |
ATE198152T1 (de) | Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe | |
BR0010869A (pt) | Método para administrar um corticosteróide a um segmento posterior de um olho e dispositivo de liberação sustentada implantável | |
MXPA02011624A (es) | Uso de una composicion de celecoxib para alivio rapido del dolor. | |
TR200001998T1 (tr) | Kontrollü salıverilen tolterodin uygulamak için ilaç formülasyonu | |
MX2008000099A (es) | Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones. | |
ES2007100A6 (es) | Procedimiento para la obtencion de un sistema terapeutico oral a base de carbamazepina. | |
CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
GB9313484D0 (en) | Drug system ii | |
ES2158101T3 (es) | Formulaciones farmaceuticas efervescentes que contienen microcapsulas biodegradables de liberacion controlada. | |
SG146638A1 (en) | Pharmaceutical delivery system | |
IL140848A0 (en) | Treatment regimen for administration of phenylacetylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate | |
WO2000013662A3 (en) | Medicated chewing gum delivery system for nicotine | |
DK0856312T3 (da) | Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme | |
HK1038310A1 (en) | Compositions and methods for treating intracellular infections. | |
MY126321A (en) | Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer. | |
ATE135203T1 (de) | System zur peroralen arzneimittelabgabe | |
HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
UA37510A (uk) | Спосіб лікування загрози передчасного переривання вагітності | |
MD1568G2 (ro) | Metodă de tratament al bolii arşilor în perioada şocului combustional | |
MY124346A (en) | Medicated chewing gum delivery system for nicotine |